A/Prof Craig Haifer

MBBS (Hons) FRACP

Associate Professor Craig Haifer is a consultant Gastroenterologist and Hepatologist, with a strong interest in Crohn’s disease, ulcerative colitis, the gut microbiome, faecal microbiota transplantation, bowel cancer screening, irritable bowel syndrome and liver disorders.

Clinical Expertise

Craig grew up in Bondi before moving to Melbourne to complete his undergraduate medical degree. He received a Monash University scholarship and completed a Bachelor of Medicine and Surgery with Honours in 2010. He completed his specialist training at the Austin Hospital, Monash Health and Western Health in Melbourne before returning to Sydney to complete further fellowships in inflammatory bowel disease at St Vincent’s Hospital and Concord Repatriation General Hospital.

Prof Haifer became a Fellow of the Royal Australian College of Physicians in Gastroenterology and Hepatology in 2017 and has since worked as a specialist gastroenterologist at St Vincent’s Hospital and Concord Hospital in Sydney. 

Prof Haifer has admitting rights at St Vincent’s Public Hospital, Concord Repatriation General Hospital and St Vincent’s Private Hospital. He performs endoscopic procedures at Double Bay Day Hospital and also visits regional NSW on a regular basis, providing support to Wagga Wagga Regional Referral Hospital.

Research

In addition to his clinical work, Craig is heavily involved in research and education. He is in the final stages of completing a PhD through the University of Sydney assessing the role of faecal microbiota transplantation (FMT) in gastrointestinal diseases. He was awarded the Vincent Fairfax Family Foundation Research Entry Scholarship through the Royal Australasian College of Physicians and has been award over $300,000 worth of research funding through organisations including the Gastroenterological Society of Australia, Gutsy Group and The St Vincent’s Clinic Foundation. 

He has published extensively in the management of Crohn’s disease, ulcerative colitis, liver disease and the microbiome. He is the lead author on the Australian guidelines of the use of FMT and continues to coordinate a trial utilising oral FMT in the management of ulcerative colitis (LOTUS Study)

Ongoing research is an important part of his clinical practice and he continues to recruit for numerous local and international clinical trials. 

For further information click here.